Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
| Revenue (TTM) | $30.32M |
| Gross Profit (TTM) | $11.43M |
| EBITDA | $-25.96M |
| Operating Margin | -194.50% |
| Return on Equity | -240.40% |
| Return on Assets | -44.00% |
| Revenue/Share (TTM) | $1.83 |
| Book Value | $0.25 |
| Price-to-Book | 12.32 |
| Price-to-Sales (TTM) | 1.81 |
| EV/Revenue | 1.441 |
| EV/EBITDA | -11.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -53.90% |
| Shares Outstanding | $17.18M |
| Float | $12.41M |
| % Insiders | 49.00% |
| % Institutions | 27.06% |
Volatility is currently contracting
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
– Company's achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advancement of the Company's global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1'27 – WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it has achieved the pre-defined revenue, growth and operational milestones required to increase the maximum commitment amount under its credit facility with an entity controlled by Paul B.
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C.
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced completion of enrollment of the first pivotal clinical trial (COVE-2) of its global Phase 3 program evaluating YCANTH® (VP-102) for the treatment of common warts.
Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028.
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd.
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRCA and any ticker you trade — then tracks every position and per-strategy win rate.
